Sigma-Tau Group is a leading research-based pharmaceutical company headquartered in Pomezia, Italy with more than 2,500 employees worldwide.
Sigma-Tau Group focuses its research and development on cardiovascular disease, metabolism, oncology, immunology, and the central and peripheral nervous systems. It has 30 clinical indications studied with 17 proprietary molecules – most of which are new and original – among 47 projects.
Sigma-Tau is also dedicated to creating novel therapies for the unmet needs of patients with rare diseases. Truly unique in its field, Sigma-Tau places its considerable scientific resources behind the discovery, development and distribution of compounds that benefit the few.
Sigma-Tau Group has operating subsidiaries throughout Europe and the United States and maintains a presence in all of the world’s major pharmaceutical markets.